Skip to main content
. Author manuscript; available in PMC: 2017 Nov 8.
Published in final edited form as: Oral Oncol. 2015 Dec 15;53:74–79. doi: 10.1016/j.oraloncology.2015.11.014

Figure 1.

Figure 1

Clinical responses to therapy. A) Best responses for patients treated with IPI-926 and cetuximab. B) Progression free survival by HPV status and prior cetuximab exposure. Median PFS for HPV-positive is 44 days (95% CI 39–156) versus 144 days for HPV-negative cancers (95% CI 56–190, p=0.09).